We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.325 | 2.30 | 2.35 | 2.325 | 2.325 | 2.33 | 8,138 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 13.09M | -33.29M | -0.0320 | -0.73 | 24.22M |
Date | Subject | Author | Discuss |
---|---|---|---|
18/10/2024 10:50 | PATT Come back to the Ethernity telegram group | sutherland1 | |
18/10/2024 09:37 | 24/7/24 Q2 update. 24 days after Q end. 30/4/24 Q1 update. 30 days after Q end. 21/2/24 Full year update. Late because of errors. 7/12/23 Q3 update. Late. 20/7/23 Q2 update. 20 days after Q end. So could be update next week. | purchaseatthetop | |
18/10/2024 09:10 | 30-50 days after the quarter close, based on history. Probably nearer to the short end of that as it is not an H1 or FY trading update. | hpcg | |
18/10/2024 08:24 | When is the next update due? | r9505571 | |
18/10/2024 07:51 | Easier to blame me. Actually I blame the CEO. Happily here the actual prescription figures can be relied on. Assuming that they don’t screw it up again like they did in 2023 when they overstated them by 15%. Maddison had to go after that. On the other hand that is what creates the value opportunity here and now. The share price is still far below the price it was at when the clusterfu*k happened and since then the Sallyport invoice financing and China milestone $5.7m have transformed the balance sheet and cashflows while cash breakeven EBITDA is within sight subject to 45k+ prescriptions in Q3. Here’s hoping. | purchaseatthetop | |
18/10/2024 07:43 | Seems like some have lost a fortune by taking PURCHASEATTHETOP BB post as a in depth research paper 😁. You can only blame yourself...! | razoblade | |
18/10/2024 01:00 | There is only one likely outcome and it isn’t good. | antonagis | |
17/10/2024 21:00 | Just filter, It’s not material or significant to outcome of STX shareprice. | fishboy | |
17/10/2024 19:19 | PURCHASEATTHETOP telling people we’re crackpots is priceless. He’s gone from chat to chat since November 2020 posting all day everyday until that particular stock is worthless, then moves on. His posting history tells all. He’s done it on BUSHVELD, ITX, ENET to name just a few. Anyone stupid enough to take any of his unsubstantiated posts seriously is just as bad. On the face of it it may seem he is genuine but his history tells the real story. A parasite has nothing on this guy. | antonagis | |
17/10/2024 16:44 | If STX gets to 15p the bailiffs will be happy. You'll finally have made a profit on an investment to pay back that polio charity | dplewis1 | |
17/10/2024 16:43 | 23/5/24 Hardman repot forecast Q2 24 34,550 Q3 24 46,500 Q4 24 63,200 Actual Q2 24 was 36,400 so 1,850 odd higher than the 34,550 estimate. Would be very nice if they exceeded forecasts for Q3 snd Q4! Also rare that forecasts are exceeded. | purchaseatthetop | |
17/10/2024 15:19 | Sadly husbod I was in STX from about 2020 snd sold on the way down when I realised that it would be several years before light dawned. The light in now growing strongly on the horizon snd good times are getting nearer. Russ is a weird troll who follows me everywhere. Like numbers of others. But I filter the morons so only know when posts say they are here! Cannot wait to see if he is still here in six months when STX is 15p. | purchaseatthetop | |
17/10/2024 14:53 | After many years of telling everyone how good ENET would be from 62 down to.23. He is now over here sharing his wisdom. The man is a crackpot fraud. Do not listen to a word he says. His success in shares is 100% loss. You have all been warned. | russ42 | |
17/10/2024 08:02 | Bottom of the channel again. It was 3.5p, then 4.1p, now 4.6p. Might return to rising into the news period. | purchaseatthetop | |
16/10/2024 18:04 | A 400% gain over the next 6 months will see me nicely in profit.The impending news needs to be strong to enable our recovery to continue | base7 | |
16/10/2024 16:15 | Reviewwworld, what are the forward looking negatives you see here? | hms_trader | |
16/10/2024 15:57 | This is still a 400+% gain in 6 months no matter how you look at this! | bolitix | |
16/10/2024 14:52 | Yup. Only ever ever ever looks at the positive. When they announced shocking results he would fill the board with "actually reading between the lines this is seriously positive" and other type nonsense | reviewwworld | |
16/10/2024 12:55 | Another two weeks and we will have Q3 24 US sales and Rx plus new UK figures The UK sales seem finally to becoming exponential growth so August figures on 31/12/24 will be interesting. The CEO talks about max revenues of $400m but the iron deficiency market itself will double in the next decade. Nothing to do but wait for new data but the bottom line is that dealing with IDS involves either cheap salt based drugs that ruin your health, intravenous treatment that is very expensive snd invasive, or Accrufer which is orally taken and very light in bad reactions. IP protected till Nov 2035. Gotta be interesting! | purchaseatthetop | |
16/10/2024 11:26 | Just a short drift back before rising towards 6p. | purchaseatthetop | |
16/10/2024 11:21 | chart is healthy, as far as i can tell. just need a bit of time and patient | qipincha | |
16/10/2024 08:47 | It’s only taken several years for people to realise what PURCHASEATTHETOP is all about. | antonagis | |
16/10/2024 05:28 | Just filter him. | fishboy | |
15/10/2024 16:07 | Unfortunately I knew the bounce was over the minute he started rambling | reviewwworld |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions